Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
Atosiban (RW22164; Tractocile; RWJ-22164) is a novel and potent peptide-based oxytocin and vasopressin antagonist with the potential to be used for spontaneous preterm labor. It is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra). Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane.
ln Vitro |
Atosiban prevents the myometrium from releasing IP3 through oxytocin. Both the intracellular calcium released from myometrial cells' sacroplasmic reticulum and the external Ca2+ influx through voltage-gated channels are decreased. Furthermore, atosiban can prevent decidua from releasing PGE and PGF when oxytocin is present [1].
|
---|---|
ln Vivo |
Atoposiban influences the physiological effects of arginine vasopressin on the fetal-maternal cardiovascular and renal systems. The posterior pituitary hormones oxytocin and arginine vasopressin differ in structure by just two amino acids. A trial using atosiban for one hour did not result in any changes to the cardiovascular systems of the mother or the fetus in late-gestation sheep [1]. In the parabrachial nucleus of mice, atosiban inhibits the activation of neurons that express the oxytocin receptor [2].
|
References |
[1]. Sanu O, et al. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther Clin Risk Manag. 2010 Apr 26;6:191-9.
[2]. Philip J Ryan, et al. Oxytocin-receptor-expressing Neurons in the Parabrachial Nucleus Regulate Fluid Intake. Nat Neurosci. 2017 Dec;20(12):1722-1733. |
Molecular Formula |
C43H67N11O12S2
|
---|---|
Molecular Weight |
994.19
|
Exact Mass |
993.4412
|
CAS # |
90779-69-4
|
Related CAS # |
Atosiban acetate;914453-95-5
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
S1C([H])([H])[C@@]([H])(C(N2C([H])([H])C([H])([H])C([H])([H])[C@@]2([H])C(N([H])[C@]([H])(C(N([H])C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])N([H])[H])=O)=O)N([H])C([C@]([H])(C([H])([H])C(N([H])[H])=O)N([H])C([C@]([H])([C@@]([H])(C([H])([H])[H])O[H])N([H])C([C@]([H])([C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])N([H])C([C@@]([H])(C([H])([H])C2C([H])=C([H])C(=C([H])C=2[H])OC([H])([H])C([H])([H])[H])N([H])C(C([H])([H])C([H])([H])S1)=O)=O)=O)=O)=O
|
Synonyms |
Atosiban RWJ-22164 RW22164 TractocileRWJ22164 RW-22164 TractocileRWJ 22164
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~16.67 mg/mL (~16.77 mM)
DMSO : ≥ 16.67 mg/mL (~16.77 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (1.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (1.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (1.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.0058 mL | 5.0292 mL | 10.0584 mL | |
5 mM | 0.2012 mL | 1.0058 mL | 2.0117 mL | |
10 mM | 0.1006 mL | 0.5029 mL | 1.0058 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.